Aarón Pantoja Angles

Aarón Pantoja Angles

Auto-generated profile, based on publicly available information

Aarón Pantoja Angles

Laboratory for Genome Engineering and Synthetic Biology, Division of Biological Sciences, 4700 King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SCShahid Chaudhary
Shahid Chaudhary
ZAZahir Ali
Zahir Ali
MTMuhammad Tehseen
Muhammad Tehseen
EHEvan Haney
Evan Haney
APAarón Pantoja-Angles
Aarón Pantoja-Angles
MMMagdy Mahfouz
Magdy Mahfouz
Antimicrobial peptides (AMPs) are promising next-generation antibiotics that can be used to combat drug-resistant pathogens. However, the high cost involved in AMP synthesis and their short plasma half-life render their clinical translation a challenge. To address these shortcomings, we report efficient production of bioactive amidated AMPs by transient expression of glycine-extended AMPs in Nicotiana benthamiana line expressing the mammalian enzyme peptidylglycine α-amidating mono-oxygenase (PAM). Cationic AMPs accumulate to substantial levels in PAM transgenic plants compare to nontransgenic N. benthamiana. Moreover, AMPs purified from plants exhibit robust killing activity against six highly virulent and antibiotic resistant ESKAPE pathogens, prevent their biofilm formation, analogous to their synthetic counterparts and synergize with antibiotics. We also perform a base case techno-economic analysis of our platform, demonstrating the potential economic advantages and scalability for industrial use. Taken together, our experimental data and techno-economic analysis demonstrate the potential use of plant chassis for large-scale production of clinical-grade AMPs.


30 August 2025 in bioRxiv
Verified
Preprint
Open access
APAaron Pantoja-Angles
Aaron Pantoja-Angles
AZAli Zahir
Ali Zahir
SASherin Abdelrahman
Sherin Abdelrahman
CBCynthia Olivia Baldelamar-Juárez
Cynthia Olivia Baldelamar-Juárez
SCShahid Chaudhary
Shahid Chaudhary
MMMagdy Mahfouz
Magdy Mahfouz
Synthetic biology enables the integration of sophisticated genetic programs into microorganisms, transforming them into potent vehicles for therapeutic applications. Engineering strategies for microorganisms are rapidly evolving, offering promising solutions for cancer therapy, microbiome modulation, digestive health support, and beyond. Developing novel tools to engineer safe, nonpathogenic microbial platforms is essential for advancing clinical therapies. In this work, we present an innovative engineering approach for the probiotic Escherichia coli Nissle (EcN), aimed at creating a safe and efficient chassis for the bioproduction of therapeutics. The EcN endogenous pM1 and pM2 plasmids were cured and re-engineered to introduce a CRISPR-Cas12 chromosome shredding device and a therapeutic-producing genetic circuit, thereby generating a nonproliferative therapeutic-delivery system. Next, we build an AI-based bioinformatic pipeline to predict Anticancer-Cell-Penetrating Peptides (ACCPP) candidates. As a proof-of-concept, a selected ACCPP was produced in the engineered EcN chromosome-shredded (CS) chassis. This strategy yields a robust and controllable platform for the safe production and delivery of therapeutics, paving the way for the future development of microbial therapies and their clinical applications. GRAPHICAL

10 October 2026 in ACS Synthetic Biology
Verified
Journal Article
Closed access
APAaron Pantoja-Angles
Aaron Pantoja-Angles
ZAZahir Ali
Zahir Ali
SASherin Abdelrahman
Sherin Abdelrahman
CBCynthia Olivia Baldelamar-JuárEz
Cynthia Olivia Baldelamar-JuárEz
SCShahid Chaudhary
Shahid Chaudhary
MMMagdy Mahfouz
Magdy Mahfouz